Due to relatively recent and ongoing world events (eg, terrorist attacks, wars, and natural disasters), there has been a shift in attention from some of the more common psychiatric illnesses to one of the more elusive, namely, posttraumatic stress disorder (PTSD). PTSD is a severe, and often chronic, condition that can lead to significant morbidity and mortality. Although originally a condition seen primarily among war veterans, PTSD is now becoming more prevalent in the general community. PTSD often presents concurrently with other conditions, such as depression, bipolar, anxiety/panic disorders, and alcohol and drug abuse. Because of this, PTSD often goes unrecognized and is underdiagnosed in clinical practice. Thus, an opportunity for pharmacist intervention exists, both in the institution and in the community. With proper education and training, pharmacists can be efficient in screening for signs and symptoms of PTSD, triaging appropriate patients, and can play an integral role in managing the diverse array of drug therapy options for PTSD.
NarrowWERaeDSRobinsLNRegierDA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys’ estimates. Arch Gen Psychiatry. 2002;59(2):115–123.
DipiroJTTalbertRLYeeGCPharmacotherapy: A Pathophysiologic Approach. 7th ed. McGraw Hill: New York, NY; 2008:1179–1188.
4.
ChavezB. A review of pharmacotherapy for PTSD. US Pharm. 2006;31(11):31–38.
5.
Veterans Affairs/Department of Defense. Management of Traumatic Stress Disorder and Acute Stress Reaction: Clinical Practice Guideline. Washington, DC: Veterans Affairs/Department of Defense; 2011.
6.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Fourth edition. Text Revision. Washington, DC: American Psychiatric Association; 2000.
7.
American Psychiatric Association. Guideline watch (March 2009): Practice Guideline for the treatment of patients with Acute Stress Disorder and Posttraumatic Stress Disorder. Washington, DC: American Psychiatric Association; 2009.
8.
Institute of Medicine: Treatment of PTSD: An Assessment of the Evidence. Washington, DC: National Academies Press. http://www.iom.edu/?id=47402, 2007.
9.
YehudaR. Risk and resilience in posttraumatic stress disorder. J Clin Psychiatry. 2004;65(suppl 1):29–36.
10.
NuttDJ. The psychobiology of posttraumatic stress disorder. J Clin Psychiatry. 2000;61(suppl 1):24–29.
11.
KentJMMathewSJGormanJM. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002;52(10):1008–1030.
12.
FisherPMMeltzerCCPriceJCMedial prefrontal cortex 5-HT2a density is correlated with amygdale reactivity, response habituation and functional coupling. Cereb Cortex. 2009;19(11):2499–2507.
13.
SeedatSWarwickJvan HeerdenBSingle photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord. 2004;80(1):45–53.
14.
ChambersRABremnerJDMoghaddamBGlutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry. 1999;4(4):274–281.
15.
FoaEKeaneTFriedmanMJ. Guidelines for treatment of PTSD. J Trauma Stress. 2000;13(4):539–588.
16.
StewartCWrobelT. Evaluation of the efficacy of pharmacotherapy and psychotherapy in treatment of combat-related post-traumatic stress disorder: a meta-analytic review of outcome studies. Mil Med. 2009;174(5):460–469.
17.
WilsonSABeckerLATinkerRH. Eye movement desensitization and reprocessing (EMDR) treatment for psychologically traumatized individuals. J Consult Clin Psychol. 1995;63(6):928–937.
18.
BradyKTPearlsteinTAsnisGMEfficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283(14):1837–1844.
19.
DavidsonJRRothbaumBOvan der KolkBAMulticenter, double-blinded comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58(5):485–492.
20.
SteinDJDavidsonJSeedatSBeebeK. Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003;4(10):1829–1838.
21.
SchneierFRNeriaYPavlicovaMCombined prolonged exposure therapy and paroxetine for PTSD related to the world trade center attack: a randomized controlled trial. Am J Psychiatry. 2011;169(1):80–88.
22.
EscalonaRCaniveJCalaisLFluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depression Anxiety. 2002;15(1):29–33.
23.
Van der KolkBASpinazzolaJBlausteinMEA randomizes clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long term maintenance. J Clin Psychiatry. 2007;68:37–46.
24.
TuckerPPotter-KimballRWyattDBCan physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacology Bull. 2003;37(3):135–149.
25.
MartenyiFBrownEBCaldwellCD. Failed efficacy of fluoxetine in the treatment of post-traumatic stress disorder: results of a fixed-dose, placebo-controlled study. JCP. 2007;27(2):166–170.
26.
SchoenfeldFBMarmarCRNeylanTC. Current concepts in pharmacotherapy of posttraumatic stress disorder. Psychiatric Serv. 2004;55(5):519–531.
27.
KeltnerNLMcAfeeKMTaylorCL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care. 2002;38(3):111–116.
28.
DavidsonJRothbaumBOTuckerPVenlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo controlled study. J Clin Psychopharmacol. 2006;26(3):259–267.
29.
DavidsonJRTWeislerRHButterfieldMIMirtazapine versus placebo in posttraumatic stress disorder: a pilot study. Biol Psychiatry. 2003;53(2):188–191.
30.
KimWPaeCChaeJThe effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy. Psychiatry Clin Neurosci. 2005;59(6):743–747.
31.
BoerTD. The pharmacologic profile of mirtazapine. J Clin Psych. 1996;67(supp 4):19–25.
32.
McRaeALBradyKTMellmanTAComparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety. 2004;19(3):190–196.
33.
KostenTRFrankJBDanEPharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179(6):366–370.
34.
DavidsonJRKudlerHSSaundersWBPredicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry. 1993;150(7):1024–1029.
35.
PivacNKozaric-KovacicD. Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features. Croat Med J. 2006;21:185–187.
36.
HammerMBDeitschSEBrodrickPSQuetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003;23(1):15–20.
37.
AhearnEPMusseyMJohnsonCQuetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol. 2006;21(1):29–33.
38.
PaeCULimHKPeindlKThe atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2008;23(1):1–8.
39.
KrystalJHRosenheckRACramerJAAdjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011;306(5):493–502.
40.
HamnerMBBrodrickPSLabbateLA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13(3):141–146.
41.
BerlantJvan KammenDP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63(1):15–20.
42.
HertzbergMAButterfieldMIFeldmanMEA preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45(9):1226–1229.
43.
DavidsonJRBradyKMellmanTAThe efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007;27(1):85–88.
44.
LipperSDavidsonJRTGradeTAPreliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986;27(12):849–854.
DavisLLDavidsonJRWardLCDivalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008;28(1):84–88.
47.
HamnerMBFaldowskiRARobertSA preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry. 2009;21(2):89–94.
48.
RaskindMAPeskindERHoffDJA parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with posttraumatic stress disorder. Biol Psychiatry. 2007;61(8):928–934.
49.
TaylorFBMartinPThompsonCPrazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008;63(6):629–632.
50.
TaylorFBLoweKThompsonCDaytime prazosin reduces psychological distress to trauma-specific cues in civilian trauma posttraumatic stress disorder. Biol Psychiatry. 2006;59(7):577–581.
51.
GelphinEBonneOPeriTTreatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry. 1996;57(9):390–394.
52.
KhaliliHFarsaeiSRezaeeHRole of clinical pharmacists’ intervention in detection and prevention of medication errors in a medical ward. Int J Clin Pharm. 2011;33(2):281–284.
53.
BremnerJDChronic PTSD in Vietnam Combat Veterans: course of illness and substance abuse. Am J Psychiatry. 1996; 153:369–375.
